These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 10948587

  • 1. [Experimental models, of Parkinson disease].
    Luquin MR.
    Rev Neurol; ; 31(1):60-6. PubMed ID: 10948587
    [Abstract] [Full Text] [Related]

  • 2. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P, Marsden CD.
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [Abstract] [Full Text] [Related]

  • 3. [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
    Luquin MR, Obeso JA, Herrero MT, Laguna J, Martínez-Lage JM.
    Neurologia; 1991 Oct; 6(8):287-94. PubMed ID: 1790005
    [Abstract] [Full Text] [Related]

  • 4. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
    Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci ME, Canteras NS, Da Cunha C.
    J Neurosci Methods; 2005 Oct 15; 148(1):78-87. PubMed ID: 15939479
    [Abstract] [Full Text] [Related]

  • 5. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies.
    Harik SI, Riachi NJ, Hritz MA, Berridge MS, Sayre LM.
    J Pharmacol Exp Ther; 1993 Aug 15; 266(2):790-5. PubMed ID: 8355208
    [Abstract] [Full Text] [Related]

  • 6. Experimental models of Parkinson's disease: insights from many models.
    Tolwani RJ, Jakowec MW, Petzinger GM, Green S, Waggie K.
    Lab Anim Sci; 1999 Aug 15; 49(4):363-71. PubMed ID: 10480640
    [Abstract] [Full Text] [Related]

  • 7. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H, Aimi Y, Nagatsu I, Taki K, Kudo M, Arai R.
    Neurosci Res; 2007 Sep 15; 59(1):1-7. PubMed ID: 17586078
    [Abstract] [Full Text] [Related]

  • 8. The possible role of iron in the etiopathology of Parkinson's disease.
    Youdim MB, Ben-Shachar D, Riederer P.
    Mov Disord; 1993 Sep 15; 8(1):1-12. PubMed ID: 8419792
    [Abstract] [Full Text] [Related]

  • 9. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L, Garris BL, Garris DR, Lau YS.
    Neuroscience; 2006 Jun 19; 140(1):67-76. PubMed ID: 16533572
    [Abstract] [Full Text] [Related]

  • 10. [Evaluation of motor disorders in animal models of Parkinson's disease].
    Campos-Romo A.
    Rev Neurol; 2006 Jun 19; 46(3):167-74. PubMed ID: 18297625
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP, Bennett RD, Zbarsky V, Ke B, Liang YF, Higa T, Bahorun T, Aruoma OI, Dexter DT.
    J Pharm Pharmacol; 2004 May 19; 56(5):649-54. PubMed ID: 15142343
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism.
    Rolland AS, Herrero MT, Garcia-Martinez V, Ruberg M, Hirsch EC, François C.
    Brain; 2007 Jan 19; 130(Pt 1):265-75. PubMed ID: 17148469
    [Abstract] [Full Text] [Related]

  • 18. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
    Yuan H, Sarre S, Ebinger G, Michotte Y.
    J Neurosci Methods; 2005 May 15; 144(1):35-45. PubMed ID: 15848237
    [Abstract] [Full Text] [Related]

  • 19. [Search for the cause of Parkinson's disease].
    Langston JW.
    Arch Neurobiol (Madr); 1991 May 15; 54(6):264-71. PubMed ID: 1811457
    [No Abstract] [Full Text] [Related]

  • 20. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
    Rojo AI, Cavada C, de Sagarra MR, Cuadrado A.
    Exp Neurol; 2007 Nov 15; 208(1):120-6. PubMed ID: 17880941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.